AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04016792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once daily
Trial: NCT04016792
Drug: 200 mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg SPN-812 will be administered once daily and compared to Placebo
Trial: NCT01651143
Drug: SAR100842
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablets~Route of administration: oral
Trial: NCT01651143
Drug: Placebo (for SAR100842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablets~Route of administration: oral
Trial: NCT02894138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00618930
Drug: Moviprep®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of Moviprep®
Trial: NCT01962181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05055895
Drug: Anticholinergic burden
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1.
Trial: NCT00219583
Drug: UK-390,957
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02961166
Drug: IgM enriched Immunoglobulins
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for 3 days
Trial: NCT02707250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
Trial: NCT00269542
Drug: Zinc and iron folic acid - Intervention
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
Trial: NCT00269542
Drug: Iron Folic Acid alone - Placebo
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
Trial: NCT04060342
Drug: GB1275
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04498741
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive rosuvastatin once daily on Day 1 and Day 13
Trial: NCT04080297
Drug: oral capsule of Q-122
RxNorm normalized name: ubidecarenone / vitamin E Oral Capsule [Q-Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01261741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive matching placebo tablets once daily
Trial: NCT00292188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00795808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet tds for 6 months
Trial: NCT04449757
Drug: Bicarbonated Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
Trial: NCT00812422
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one dose of Ibuprofen 5 or 10 mg/kg
Trial: NCT01034787
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
Trial: NCT01936519
Drug: Calcineurin Inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
Trial: NCT01764295
Drug: DWJ1276
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01764295
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01764295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02744391
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02276898
Drug: Hypertonic Saline 7%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARI Hyper-Sal™ Sodium Chloride Solution - 7%
Trial: NCT02276898
Drug: Isotonic Saline 0.9% (Placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00046449
Drug: Investigational Seasonal Affective Disorder (SAD) Drug
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR MANIA AND BIPOLAR DISORDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01455337
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg qd
Trial: NCT01572545
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
Trial: NCT00040937
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PBSC collection: 1 mg/m2 IV over 45-60 mins day 0
Trial: NCT04292886
Drug: Vitamin C and femoston
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and femoston
Trial: NCT00558909
Drug: placebo for BI 44847
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02960061
Drug: Hyperthermic intraperitoneal perfusion chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
Trial: NCT02960061
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
Trial: NCT00771381
Drug: 18F-FAZA PET scan
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
Trial: NCT00771381
Drug: FluGlucoScan Injection (18F-FDB) PET scan
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
Trial: NCT04561687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and nasal budesonide
Trial: NCT00941057
Drug: BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
Trial: NCT00941057
Drug: BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
Trial: NCT01566357
Drug: Tooth Mousse
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01566357
Drug: MI Paste Plus
RxNorm normalized name: Calcium Phosphate/Sodium Fluoride 0.2% Oromucosal Cream [GC MI PASTE PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01566357
Drug: Elmex Erosion Protection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00578071
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
Trial: NCT01791153
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
Trial: NCT01791153
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
Trial: NCT02918747
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
Trial: NCT02918747
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
Trial: NCT02537873
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose in gelatin capsule
Trial: NCT03408756
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive methotrexate through oral or subcutaneous route of administration
Trial: NCT03626506
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.
Trial: NCT03626506
Drug: Indapamide
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.
Trial: NCT00025636
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025636
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03923530
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg daily
Trial: NCT00530686
Drug: Islet cell transplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
Trial: NCT02560441
Drug: IPGDP regimen chemotherapy
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02989168
Drug: GBT440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBT440: Capsules which contain GBT440 drug substance in Swedish orange
Trial: NCT03585465
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~* Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C
Trial: NCT03585465
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~* Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C
Trial: NCT01029821
Drug: Low-Molecular-Weight Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated Ankle Fracture Single planned operation
Trial: NCT01941940
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
Trial: NCT03436914
Drug: PPI
RxNorm normalized name: PPIase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
Trial: NCT01301508
Drug: AN2728 ointment, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2728 ointment, 2%, applied twice daily for 6 weeks
Trial: NCT01301508
Drug: AN2728 ointment vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2728 ointment vehicle applied twice daily for 6 weeks
Trial: NCT01124708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
Trial: NCT04451603
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors
Trial: NCT01086475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
Trial: NCT03372811
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT03331562
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline solution for injection
Trial: NCT01832675
Drug: Xylocain, cutaneous spray, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
Trial: NCT01679587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of matching placebo will be given in each treatment arm
Trial: NCT02246439
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04551911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mcg calcifediol Extended-Release (ER) Capsule
Trial: NCT03734211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
Trial: NCT00380692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02556788
Drug: CD5789 (trifarotene) 50µg/g Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
Trial: NCT02556788
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied once daily during 12 weeks.
Trial: NCT01706627
Drug: 10 mg Melatonin
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active Comparator: Drug: Melatonin 10 mg
Trial: NCT01706627
Drug: 20 mg Melatonin
RxNorm normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active Comparator: Drug: Melatonin 20 mg
Trial: NCT01706627
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo (identical formulation and delivery, without active ingredient)
Trial: NCT01381640
Drug: Marketed paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: marketed formulation
Trial: NCT01769339
Drug: Miconazole plus Hydrocortisone
RxNorm normalized name: hydrocortisone / miconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
Trial: NCT01381640
Drug: Experimental paracetamol formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental formulation
Trial: NCT00704730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules color and size-matched to XL184 capsules administered orally daily
Trial: NCT05000086
Drug: 99Tc methylene diphosphonate
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22mg qd，Once a day for 7 consecutive days
Trial: NCT00666848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
Trial: NCT01332578
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test product
Trial: NCT05154812
Drug: Yang Yin Fu Zheng Jie Du therapy
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Trial: NCT05154812
Drug: Routine medical care
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medical care
Trial: NCT01029158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02327117
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02637375
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02637375
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02858492
Drug: GSK2982772 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
Trial: NCT02858492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
Trial: NCT01509742
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
Trial: NCT03483207
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
Trial: NCT01744093
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg twice daily (BID orally) x 24 weeks
Trial: NCT01744093
Drug: Placebo (sugar pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg twice daily (BID orally) x 24 weeks
Trial: NCT02148861
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once-daily for 35 days
Trial: NCT02751359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg Cannabidiol
Trial: NCT03535675
Drug: Muscadine Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ellagic acid inhibits DNA Methyltransferase. DNA Methyltransferases (DNMTs) are a family of enzymes that regulate chromatin methylation and use S-adenosyl methionine (SAM) as the methyl donor. Ellagic acid's metabolite, urolithin-A inhibits the protein complex nuclear factor kappa-light-enhancer of activated B-cells (NFkB), potentially leading to increased rates of apoptosis and decreases in cancer cell proliferation. Extracts from Vitis rotundifolia have shown inhibition of the phosphatidylinositol 3-kinase-Akt pathway.
Trial: NCT03535675
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsules are rice flour that will be placed in white opaque capsules identical to the ones used for MPX.
Trial: NCT04111406
Drug: Current practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural insertion and epidural drug administration depend on anesthetist in charge